COVID-19 Stroke is Unique as the VWF/ADAMTS13 Axis Plays a Key Role in Thromboinflammatory Response

Medical News: Understanding the Link Between COVID-19 and Stroke
The COVID-19 pandemic has led to many unexpected health complications, and one of the most concerning is the increased risk of ischemic stroke in some patients. A groundbreaking study conducted by researchers from The University of Manchester, The University of Leeds, The University of Edinburgh, and the Northern Care Alliance NHS Foundation Trust in the United Kingdom, has shed light on a unique mechanism that could explain why COVID-19 patients may be at a higher risk of stroke. Their findings suggest that the Von Willebrand Factor (VWF) and ADAMTS13 axis plays a critical role in the thromboinflammatory response observed in post-stroke COVID-19 patients.


COVID-19 Stroke is Unique as the VWF/ADAMTS13 Axis Plays a Key Role in Thromboinflammatory Response

Stroke is a leading cause of death and disability worldwide, and understanding the underlying mechanisms that make COVID-19-associated strokes different is crucial for improving treatment strategies. This Medical News report delves into the latest findings from this study, explaining in simple terms why COVID-19 stroke is unique.
 
What the Study Investigated
The research team focused on the VWF/ADAMTS13 axis, a crucial pathway involved in blood clotting and inflammation. VWF is a glycoprotein that helps blood clot by promoting platelet adhesion, while ADAMTS13 is an enzyme that regulates VWF by breaking it down into smaller, less reactive pieces. A healthy balance between VWF and ADAMTS13 is essential for normal blood flow and clotting.
 
COVID-19 has been known to trigger an inflammatory response that affects various organs, including the brain. The researchers wanted to determine how the virus influences the VWF/ADAMTS13 balance and whether this contributes to an increased risk of stroke. To do this, they analyzed blood samples from three groups:
 
-COVID-19 negative ischemic stroke patients
-COVID-19 positive ischemic stroke patients
-Non-stroke control participants

By comparing these groups, they aimed to uncover differences in thromboinflammatory markers and assess whether COVID-19 worsens stroke-related blood clotting abnormalities.
 
Key Findings of the Study
1. Imbalance in the VWF/ADAMTS13 Axis
One of the most significant discoveries was that COVID-19-positive stroke patients had higher levels of VWF and lower levels of ADAMTS13, leading to an imbalance that favors excessive blood clotting. This imbalance was not observed in COVID-19-negative stroke patients, suggesting that the virus directly influences the blood clotting process.
 
Moreover, the study found that COVID-19-positive stroke patients had elevated ultra-large VWF (UL-VWF) levels, which are particularly prone to forming dangerous blood clots. This indicates that COVID-19 may create an environment where blood clots form more easily, increasing the risk of ischemic stroke.
 
2. The Rol e of Inflammation (IL-6 Connection)
The study also identified Interleukin-6 (IL-6), a key inflammatory marker, as a potential driver of the VWF/ADAMTS13 imbalance. IL-6 was found to be positively correlated with VWF levels and negatively correlated with ADAMTS13 levels, suggesting that inflammation caused by COVID-19 contributes to the increased clotting risk. This aligns with previous research showing that severe COVID-19 cases are associated with “cytokine storms”, where excessive inflammation leads to widespread tissue damage and organ failure.
 
3. Blood Clotting and Fibrinolysis Changes
The research also examined fibrinogen and D-dimer levels, both of which are markers of blood clot formation and breakdown. While fibrinogen levels were elevated in both stroke groups, D-dimer levels remained within normal ranges in COVID-19-positive stroke patients, suggesting that despite increased clotting, there was no widespread disseminated intravascular coagulation (DIC), a severe condition seen in some COVID-19 cases.
 
Additionally, tissue plasminogen activator (tPA), which helps dissolve blood clots, was significantly elevated in COVID-19 stroke patients, further indicating an ongoing thromboinflammatory response. This suggests that while the body is trying to counteract excessive clotting, the overall balance remains disrupted, increasing the risk of severe strokes.
 
Why These Findings Matter
These findings highlight the unique nature of strokes in COVID-19 patients, suggesting that standard stroke treatments may not be sufficient for those who have had a SARS-CoV-2 infection. The study underscores the need for a more targeted approach to managing stroke risk in COVID-19 patients, potentially through therapies that restore the balance of the VWF/ADAMTS13 axis.
 
Moreover, the identification of IL-6 as a key factor in this imbalance suggests that anti-inflammatory treatments, such as IL-6 inhibitors, could play a role in preventing stroke complications in COVID-19 patients. This has significant implications for how we treat patients recovering from COVID-19, especially those at high risk of stroke due to underlying health conditions.
 
Study Limitations and Future Research
While the study provides valuable insights, there are some limitations. The sample size was relatively small, with 24 COVID-19-positive stroke patients, 22 COVID-19-negative stroke patients, and 23 non-stroke controls. Additionally, the researchers only analyzed blood samples at the time of admission, meaning they could not track changes over time or assess long-term stroke outcomes.
 
Future research should focus on:
-Larger sample sizes to confirm these findings in diverse populations
-Longitudinal studies to monitor how the VWF/ADAMTS13 axis evolves over time
-Clinical trials to test whether targeted anti-inflammatory treatments can reduce stroke risk in COVID-19 patients
 
Conclusion
This study provides compelling evidence that COVID-19-associated stroke is unique due to the involvement of the VWF/ADAMTS13 axis in the thromboinflammatory response. The imbalance observed in COVID-19 stroke patients suggests that the virus significantly alters blood clotting mechanisms, increasing the risk of severe strokes.
 
Importantly, these findings open new avenues for potential treatments, including targeted anti-inflammatory and anticoagulant therapies that address the specific clotting abnormalities seen in COVID-19 patients. As our understanding of post-COVID complications grows, studies like this play a crucial role in guiding medical professionals toward better prevention and treatment strategies.
 
The study findings were published in the peer-reviewed journal: Brain and Behavior.
https://onlinelibrary.wiley.com/doi/10.1002/brb3.70348
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/sars-cov-2-increases-plasma-vwf-levels-and-decreases-adamts13-activity-raising-risk-and-worsening-outcomes-of-stroke-
 
https://www.thailandmedical.news/news/targeting-mitochondrial-dysfunction-in-cerebral-ischemia-for-better-outcomes
 
https://www.thailandmedical.news/news/astragalus-mongholicus-efficacy-in-stroke-recovery
 
https://www.thailandmedical.news/pages/thailand_doctors_listings